BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project. It also sequences the genomes of other animals, plants and microorganisms.
Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).
George McDonald Church is an American geneticist, molecular engineer, chemist, serial entrepreneur, and pioneer in personal genomics and synthetic biology. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard University and Massachusetts Institute of Technology, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard University.
CLC bio was a bioinformatics software company that developed a software suite subsequently purchased by QIAGEN.
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
Jonathan Marc Rothberg is an American scientist and entrepreneur. He is best known for his contributions to next-generation DNA sequencing. He resides in Miami, Florida.
NanoString Technologies, Inc. was a biotechnology company focused on discovery and translational research.
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Anuradha Acharya is an Indian entrepreneur. She is the founder and CEO of Ocimum Bio Solutions and Mapmygenome. She was awarded Young Global Leader by the World Economic Forum in 2011.
P. Ananda Kumar is an Indian plant molecular biologist and biotechnologist.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.
PDL BioPharma is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.
Foresite Capital (Foresite) is an American, multi-stage healthcare and life sciences investment firm headquartered in Los Angeles, and with offices in The San Francisco Bay Area and New York City. As of June 2024, the company had raised six primary funds: Foresite Capital Fund I, II, III, IV, V and VI.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
MGI or MGI Tech is a Chinese biotechnology company, which provides a line of products and technologies that serves the genetic sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in Shenzhen, Guangdong, China.
Linked-read sequencing, a type of DNA sequencing technology, uses specialized technique that tags DNA molecules with unique barcodes before fragmenting them. Unlike traditional sequencing technology, where DNA is broken into small fragments and then sequenced individually, resulting in short read lengths that has difficulties in accurately reconstructing the original DNA sequence, the unique barcodes of linked-read sequencing allows scientists to link together DNA fragments that come from the same DNA molecule. A pivotal benefit of this technology lies in the small quantities of DNA required for large genome information output, effectively combining the advantages of long-read and short-read technologies.
US$618.7 million (2023)
US$−265 million (2023)